HBV suppressed on long-term tenofovir alafenamide; switch from TDF improves safety
14 Nov 2020
byJairia Dela Cruz
Tenofovir alafenamide (TAF) keeps chronic hepatitis B virus (HBV) in check through 5 years of treatment, with an added benefit of improving bone and kidney safety outcomes in patients who have switched from tenofovir disoproxil fumarate (TDF), according to data from two ongoing phase III studies.